Gastrooesophageal reflux disease in infants

  • PIC logo
    PIC Endorsed
  • See also  

    Unsettled or crying babies 

    Key points

    1. Gastro-oesophageal reflux disease (GORD) should be differentiated from physiological gastro-oesophageal reflux, which is common in healthy, thriving babies and does not require specific investigations or management
    2. GORD is not a common cause of unexplained crying, irritability or distressed behaviour in otherwise healthy infants 
    3. Empiric use of acid suppression for unsettled infants is not effective and may cause harm 
    4. The natural history of GORD is of resolution with time; any therapy commenced should be reviewed regularly


    Gastro-oesophageal reflux (GOR) is the passage of gastric contents into the oesophagus, often with effortless vomiting, or 'possets'. It is a physiological process that occurs several times a day in healthy infants.     

    Gastro-oesophageal reflux:
    • is common, affecting at least 40% of infants
    • usually begins before 8 weeks of age, peaks at 4 months and resolves by 1 year of age in majority of cases
    • does not cause crying and irritability in healthy infants. Infant crying peaks at 6-8 weeks, and hence some babies with simple GOR may also be unsettled
    • rarely require investigations
    • can usually be managed with parental education, support and anticipatory guidance

    There is insufficient evidence to support the diagnosis or management of "silent reflux"

    Gastro-oesophageal reflux disease is when GOR causes vomiting with:

    • refusal to feed
    • pronounced irritability with feeding
    • aspiration
    • chronic cough, wheeze
    • slow weight gain
    • haematemesis

    Cow milk protein allergy (CMPA) can present with similar symptoms to GORD

    • Blood and/or mucous in stool, chronic diarrhoea or atopic risk factors make this diagnosis more likely. See Flow Chart below.


    • Both GOR and GORD can be diagnosed on detailed history and examination 
    • Direct observation of a feed by an experienced clinician can be particularly useful to identify exacerbating factors 

    Reconsider diagnosis if any of the following red flag features are present:


    • Vomiting that is bilious; has onset >6 months of age; or is consistent and forceful
    • Significant diarrhoea or constipation
    • Fever or lethargy


    • Abdominal rigidity
    • Hepatosplenomegaly
    • Bulging fontanelle and/or increasing head circumference



    Investigations for GORD (such as barium contrast radiography, pH probe, endoscopy) are rarely necessary, and are not diagnostic. Investigations should only be considered on an individual basis after the patient has been assessed by a paediatrician.


    Simple GOR can cause considerable parental distress, and requires reassurance, support and anticipatory guidance. General measures may minimize symptoms.     

    General measures 


    • Holding the infant in a head elevated position for 20–30 minutes after feeding may reduce GOR
    • Prone sleeping or inclining the sleep surface is not recommended in infants due to the risk of SIDS

    Thickened feeds

    • In bottle fed babies, thickened feeds may reduce frequency of vomiting
    • "Anti-reflux" formulas are pre-thickened, or alternatively a thickening agent can be added to a standard formula or expressed breast milk
    • Thickened feeds can contribute to constipation
    • Ensure the infant is not being given sodium alginate (Gaviscon Infant®) as co-administration increases risk of bowel obstruction

    Optimise feeds

    • Observation and assessment of feeds by an experienced lactation consultant or Maternal Child Health Nurse (MCHN) can be helpful
    • Assess feed volumes in formula fed infants to identify overfeeding. Reducing feed volumes can reduce regurgitation but should only be considered if excessive for infant's weight. Consider a trial of smaller, more frequent feeds in these infants if practical
    • GOR alone is not an indication to change formula or stop breast feeding. One particular brand of standard cow milk formula does not confer benefit over another, nor do they vary in their content of dairy

    Specific measures for GORD

    Consider cow milk protein exclusion

    • Up to 40% of infants presenting with symptoms of GORD will have non-IgE mediated Cow Milk Protein Allergy (CMPA) 
    • Symptoms usually occur within a few weeks of exposure to cow milk protein 
    • There are no specific distinguishing features that can predict response to dietary modification, nor are any investigations helpful in CMPA 
    • Where CMPA is suspected, the infant should have a 2 week trial of strict cow milk protein elimination from their diet and referral to a paediatrician arranged
      • Breast fed infants require strict maternal dairy avoidance
      • Formula fed infants require extensively hydrolysed formula, obtained via prescription from a paediatrician. Over the counter formula options include Novalac Allergy® or Aptamil Allerpro®

    Consider acid suppressant therapy:

    Acid suppressant therapy may be indicated in specific patients with GORD (see flow chart).  When commenced, it should be instituted as a four week trial. Omeprazole, a proton pump inhibitor (PPI), is the recommended agent:

    • omeprazole: <10 kg: 5 mg once daily
    • omeprazole takes 4 days to reach maximum effect

    Studies have indicated that PPI therapy may lead to an increased risk of:

    • increased risk of community acquired pneumonia
    • increased risk of gastroenteritis
    • increased future fracture risk
    • micronutrient deficiencies

    There is no evidence to support empiric use of acid-suppressant therapy as a diagnostic trial for irritable infants

    It is important to review ongoing therapy and cease at 4 weeks if no benefit

    Surface agents

    Surface agents such as sodium alginate (Gaviscon infant ®) increases viscosity of gastric contents and can reduce episodes of visible regurgitation. There is little information available on efficacy and long-term use in infants is not recommended

    Management Flow Chart

    Gastro-oesophageal Reflux Disease in Infants

    Surgical treatment

    Surgical approaches (eg fundoplication) are reserved for children who have intractable GORD symptoms unresponsive to medical therapy or with significant complications

    Consider consultation with local paediatric team when

    • Red flag features present
    • Infant clinically unwell
    • GORD not responding to initial management, or commenced on acid suppressant therapy

    Consider transfer when

    Child requiring care beyond the comfort level of the hospital

    For emergency advice and paediatric or neonatal ICU transfers, see Retrieval Services

    Parent information

    Additional notes

    REducing MEDications in Infants (REMEDI)

    Last updated October, 2019

  • Reference List

    1. Davies I, Burman-Roy S, Murphy MS; Guideline Development Group. Gastro-oesophageal reflux disease in children: NICE guidance. BMJ. 2015. 350:g7703.
    2. Eichenwald, EC. Diagnosis and Management of Gastroesophageal Reflux in Preterm Infants. Pediatrics. 2018. 142 (1).
    3. Gonzalez Ayerbe JI, Hauser B, Salvatore S, Vandenplas Y. Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice. Pediatric Gastroenterology Hepatology and Nutrition. 2019. 22(2), p107–121.
    4. Kahrilas PJ, Shaheen NJ, Vaezi MV. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008. 135, p1392-1413.
    5. Lightdale, JR., Gremse, DA. Gastroesophageal Reflux: Management Guidance for the Pediatrician. Pediatrics. 2013. 131 (5), e1684-e1695.
    6. Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early Acid Suppression Therapy Exposure and Fracture in Young Children. Pediatrics. 2019. 144 (1).
    7. Numans ME, Lau J, de Wit NJ, et al. Short-Term Treatment with Proton-Pump Inhibitors as a Test for Gastroesophageal Reflux Disease: A Meta-Analysis of Diagnostic Test Characteristics. Ann Intern Med. 2004. 140, p518–527.
    8. Poddar, U. Gastroesophageal reflux disease (GERD) in children. Paediatrics and International Child Health. 2019. 39(1), p7-12.
    9. Tighe M, Afzal  NA, Bevan  A, Hayen  A, Munro  A, Beattie  RM. Pharmacological treatment of children with gastro‐oesophageal reflux. Cochrane Database of Systematic Reviews. 2014. Issue 11.
    10. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gatroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009. 49, p498–547.